Advanced Filters
noise

breast-cancer Clinical Trials

A listing of breast-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 2,264 clinical trials
M María Torres-Lacomba, PhD

Genitourinary Syndrome of Menopause in Breast Cancer

This randomized, single-blind clinical trial will compare the effectiveness of multimodal pelvic floor physiotherapy (PPT) and fractional CO2 vaginal laser therapy in reducing genitourinary syndrome of menopause (GSM) symptoms among breast cancer (BC) survivors. GSM, induced by cancer treatments, is common in BC survivors due to hormonal deprivation, and effective …

38 years of age Female Phase N/A

LAG3 Expression in Triple Negative Breast Cancer

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

years of age Female Phase N/A
B Barbro Kristina Linderholm, P.I.

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

18 years of age All Phase N/A
Z Zheng-Yu Hoe

Early Diagnosis of Breast Cancer-related Lymphedema

This study will conduct clinical trials to explore the mechanisms behind the development of upper limb lymphedema following breast cancer surgery. The investigators will recruit patients who have undergone breast cancer surgery and utilize Indocyanine Green (ICG) lymphography and Lymphoscintigraphy to identify the locations of lymphatic blockages. Shear Wave Elastography …

20 - 80 years of age Female Phase N/A
Y Yin U Liu, M.D

Reverse Triple Negative Immune Resistant Breast Cancer

This is a Phase II, open-label, seven-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

18 - 70 years of age Female Phase 2
A Abiodun Oni, BSc

MicroRNA Profiles in Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive disease with higher proportion of Blacks affected and in younger age groups. There is no targeted therapy unlike other types of breast cancer such as hormone positive and Human Epidermal Growth factor 2 (HER2) positive subtypes. Chemotherapy is therefore the main choice …

18 - 70 years of age Female Phase 2
M Mary D Chamberlin, MD

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

18 years of age Female Phase 1
K Kristina Rooth, PhD student

To Live Better After Breast Cancer Treatment

The most common cancer among women in Sweden is breast cancer. Advances in treatment have improved survival, but these advances have come at a steep price since most treatments impose substantial morbidity and burden on patients and their families. Furthermore, many survivors from cancer have ongoing poor health and well-being …

18 years of age All Phase N/A

FDG PET-CT in Advanced Breast Cancer

This study is a prospective cohort study comparing metabolic response evaluation by F-18 FDG PET-CT versus conventional imaging for outcome stratification in patients with advanced breast cancer receiving first-line systemic therapy.

19 years of age All Phase N/A

Basket Study for Oligo-metastatic Breast Cancer

The study will include patients with HER2-positive breast cancer and 1- 3 distant metastatic lesions, all amenable for curative intervention. Patients will be stratified by prior therapy and ER expression. In the initial baskets patients with be treated with trastuzumab-deruxtecan. Patients are treated with T-DXd 5.4mg/kg on a three weekly …

18 years of age All Phase 2

Simplify language using AI